Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741112 · ClinicalTrials.gov registry record · NA
The Long COVID-19 Wearable Device Study
A NA study of Long COVID and Chronic Fatigue Syndrome, sponsored by Scripps Translational Science Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 100,500
- Enrollment target
- 1
- Study location
NCT05741112: Recruiting NA study of Long COVID and Chronic Fatigue Syndrome, sponsored by Scripps Translational Science Institute.
NCT05741112 is a NA study of Long COVID and Chronic Fatigue Syndrome that is actively recruiting participants, run by Scripps Translational Science Institute. The registered enrollment target is 100,500 participants, above the 178-participant average among 50 other Long COVID trials with a reported enrollment target (56361% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05741112, a NA study of Long COVID and Chronic Fatigue Syndrome, is actively recruiting participants, sponsored by Scripps Translational Science Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,500 participants
- Enrollment target
- 1
- Study location
Study Summary
To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.
Primary Outcome
Will measure relapse symptom frequency, symptom severity, pain, quality of life and overall health through the analysis and measurement of change in the weekly survey responses.
Conditions Studied
Interventions
- DEVICE Wearable device
Study Locations (1)
California
- Scripps Research - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,500 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What NCT05741112 shows while recruiting
NCT05741112 is an interventional study that assigns participants to a tested intervention. Its 100,500 participants enrollment target places it among the larger protocols in the corpus, above the 178-participant average among 50 other Long COVID trials with a reported enrollment target (56361% higher).
The record links to 6 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Wearable device is the first listed.
NCT05741112 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05741112 about?
NCT05741112 is a clinical study titled "The Long COVID-19 Wearable Device Study". To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.
What is the current status of trial NCT05741112?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,500 participants. The study started on 2023-11-16. Estimated completion is 2025-12-01.
What conditions does trial NCT05741112 study?
This clinical trial studies the following conditions: Long COVID, Chronic Fatigue Syndrome, Long COVID-19, Postural Orthostatic Tachycardia Syndrome, Dysautonomia.
What interventions are being tested in trial NCT05741112?
The interventions under investigation include: Wearable device (DEVICE).
Who is sponsoring clinical trial NCT05741112?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05741112 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05741112's enrollment target sits among peer trials
100,500 1st of 50 higher than 50 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Sauna for Long Covid
RECRUITING · NA
-
Long COVID Brain Fog: Cognitive Rehabilitation Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
- NCT04869111 · 100,000 participants · NA
The BrainHealth Project
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI